- LIPID-LIKE NANOCOMPLEXES AND USES THEREOF
-
Disclosed are compounds of formula (I) below: (I), wherein each of the variables A, B, X, W, V, R1-R5, and m is defined herein. Also disclosed are pharmaceutical compositions containing a nanocomplex, wherein the nanocomplex is formed of one of the compounds, and a protein, a nucleic acid, or a small molecule; and methods of treating a medical condition with one of the pharmaceutical compositions.
- -
-
Page/Page column 32
(2019/08/26)
-
- Sulfur makes the difference: Synthesis and mesomorphic properties of novel thioether-functionalized imidazolium ionic liquid crystals
-
Novel thioether-linked imidazolium ionic liquid crystals were synthesized starting from methyl 2-mercaptoacetate. The mesomorphic properties were determined by differential scanning calorimetry (DSC), polarizing optical microscopy (POM), and X-ray diffraction. All mesogens displayed smectic A mesophase geometries with strongly interdigitated bilayer structures. Comparison of the thioether-linked imidazolium salts with the corresponding amine- and amide-linked imidazolium salts as well as simple N-alkyl-imidazolium salts showed that both mesophase width and stability increased with increasing softness of the linking unit, thus indicating the beneficial effect of sulfur. Additionally, an increase of the length of the linking unit decreased the interdigitation of the alkyl chains.
- Mansueto, Markus,Kre?, Katharina Christina,Laschat, Sabine
-
p. 6258 - 6264
(2015/03/30)
-
- LIPID COMPOUNDS FOR USE IN COSMETIC PRODUCTS, AS FOOD SUPPLEMENT OR AS A MEDICAMENT
-
The present invention relates to lipid compounds of the general formula (I): wherein ? R1 is selected from a C10-C21 alkyl, a C10-C21 alkenyl having 1-6 double bonds, and a C10-C21 alkynyl having 1-6 triple bonds; ? R2 and R3 are the same or different and are selected from hydrogen and a C1-C6 alkyl group; and X is selected from O, S, SO, SO2, Si or Se; ? n = 1 or 3; and ? P1 is selected from a hydrogen, a C10-C21 alkyl, a C10-C21 alkenyl having 1-6 double bonds, and a C10-C21alkynyl having 1-6 triple bonds, optionally substituted; or P1 is represented by: wherein P2, P3 and P4 are selected from a hydrogen, an alkyl, alkenyl, alkynyl, optionally substituted; or P1 is a phosphonate or a phosphate ester, represented by or P1 is a sulphonate or a sulphate ester, represented by wherein P5 is a hydrogen or a C1-C6alkyl; or a pharmaceutically acceptable salt, complex or solvate thereof. Also disclosed are pharmaceutical compositions and lipid compositions comprising such compounds, and such compounds for use as medicaments, in particular for the treatment of diseases related to the cardiovascular, metabolic and inflammatory disease area.
- -
-
Page/Page column 17-18
(2009/06/27)
-